Appili Therapeutics arranges $750,000 private placement

Executive Summary

• Appili Therapeutics Inc. announced a proposed non-brokered private placement of up to 30 million units at $0.025 per unit, targeting gross proceeds of up to $750,000.
• Each unit consists of one Class A common share and one-half of one common share purchase warrant, with warrants exercisable at $0.05 per share for 36 months, subject to shareholder approval.
• Net proceeds are intended for working capital and the development of product candidates, with an anticipated closing in November 2025.

Key Details

• Transaction Structure: Non-brokered private placement of up to 30 million units.
• Price: $0.025 per unit.
• Gross Proceeds: Up to approximately $750,000.
• Unit Composition: Each unit comprises one Class A common share and one-half of one common share purchase warrant.
• Warrant Terms (Investors):
  • Exercise Price: $0.05 per common share.
  • Duration: 36 months from closing.
  • Condition: Exercisable only upon receipt of shareholder approval (excluding votes of warrant holders); approval to be sought no later than the next annual general meeting. If approval is not received, warrants are not exercisable.
• Use of Proceeds: Primarily for working capital and financing the development of certain product candidates.
• Closing Conditions: Subject to regulatory approvals, including Toronto Stock Exchange (TSX) approval.
• Anticipated Closing: November 2025.
• Finder’s Fees:
  • Cash Fee: 8.0% of gross proceeds.
  • Broker Warrants: Equal to 8.0% of the number of units issued.
• Broker Warrant Terms:
  • Exercise Price: Not less than $0.02834 per common share.
  • Duration: 24 months from closing.
  • Condition: Subject to shareholder approval (excluding votes of broker warrant holders); approval to be sought no later than the next annual general meeting. If approval is not received, broker warrants are not exercisable.
• Hold Period: All securities subject to a statutory hold period of four months and one day from the date of issuance.